Core Insights - Amgen's stock price rose by 5.78% on October 1, marking a total increase of 10.07% over four consecutive days, reaching its highest level since August 2025, which has generated positive investor sentiment regarding its future market performance [1] - The stock price increase is partly attributed to recent policy interactions between the U.S. government and the pharmaceutical industry, including a drug pricing agreement between the Trump administration and Pfizer, which has provided favorable conditions for large pharmaceutical companies like Amgen [1] - Amgen has resolved a patent dispute with Bicon, avoiding potential legal risks and stabilizing market confidence in the company [1] - The company announced a $650 million investment to expand its manufacturing capabilities in the U.S., particularly in Puerto Rico, which will significantly enhance its biopharmaceutical production capacity and create nearly 750 new jobs [1] Industry Context - The positive developments surrounding Amgen support its strong market performance, but investors should remain aware of potential challenges arising from policy changes in the pharmaceutical industry [2] - Policy uncertainty will continue to be a significant factor influencing future market trends, necessitating a cautious approach from investors when formulating strategies [2] - Continuous monitoring of industry trends and company developments is crucial for investors to identify stable investment opportunities amid market volatility [2]